Search

Your search keyword '"Bernengo M.G."' showing total 109 results
Start Over Author "Bernengo M.G."
109 results on '"Bernengo M.G."'

8. Essai multicentrique de phase 2 évaluant le quisinostat oral (inhibiteur d’histone déacétylase, iHDAC) chez des patients atteints de lymphome T cutané (LTC) au stade IB-IVA déjà traité

Author

Bagot, M., primary, Child, F., additional, Romero, P. Ortiz, additional, Alvarez, R., additional, Stadler, R., additional, Weichenthal, M., additional, Alves, R., additional, Bernengo, M.G., additional, Beylot-Barry, M., additional, Cowan, R., additional, Geskin, L.J., additional, Pérez, A.F., additional, Hellemans, P., additional, Elsayed, Y., additional, Phelps, C., additional, Forslund, A., additional, Kamida, M., additional, and Zinzani, P.L., additional

Published
2013
Full Text
View/download PDF

17. Th1, Th2, Th17 and Regulatory T Cell Pattern in Psoriatic Patients: Modulation of Cytokines and Gene Targets Induced by Etanercept Treatment and Correlation with Clinical Response

Author

Quaglino, P., primary, Bergallo, M., additional, Ponti, R., additional, Barberio, E., additional, Cicchelli, S., additional, Buffa, E., additional, Comessatti, A., additional, Costa, C., additional, Terlizzi, M.E., additional, Astegiano, S., additional, Novelli, M., additional, Cavallo, R., additional, and Bernengo, M.G., additional

Published
2011
Full Text
View/download PDF

23. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role

Author

Ponti, R., primary, Bergallo, M., additional, Costa, C., additional, Quaglino, P., additional, Fierro, M.T., additional, Comessatti, A., additional, Stroppiana, E., additional, Sidoti, F., additional, Merlino, C., additional, Novelli, M., additional, Alotto, D., additional, Cavallo, R., additional, and Bernengo, M.G., additional

Published
2008
Full Text
View/download PDF

25. Serum interleukin-13 levels are increased in patients with Stevens–Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme

Author

Quaglino, P., primary, Caproni, M., additional, Osella-Abate, S., additional, Torchia, D., additional, Comessatti, A., additional, Del Bianco, E., additional, Antiga, E., additional, Frezzolini, A., additional, Schena, D., additional, Marzano, A., additional, De Simone, C., additional, Parodi, A., additional, Fabbri, P., additional, and Bernengo, M.G., additional

Published
2007
Full Text
View/download PDF

27. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma

Author

Bajetta, E., primary, Del Vecchio, M., additional, Nova, P., additional, Fusi, A., additional, Daponte, A., additional, Sertoli, M.R., additional, Queirolo, P., additional, Taveggia, P., additional, Bernengo, M.G., additional, Legha, S.S., additional, Formisano, B., additional, and Cascinelli, N., additional

Published
2006
Full Text
View/download PDF

28. T-cell receptor γ gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and i

Author

Ponti, R., primary, Quaglino, P., additional, Novelli, M., additional, Fierro, M.T., additional, Comessatti, A., additional, Peroni, A., additional, Bonello, L., additional, and Bernengo, M.G., additional

Published
2005
Full Text
View/download PDF

31. 837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma

Author

Bajetta, E., primary, Del Vecchio, M., additional, Nova, P., additional, Gattinoni, L., additional, Santinami, M., additional, Santangelo, D., additional, Daponte, A., additional, Sertoli, M.R., additional, Queirolo, P., additional, and Bernengo, M.G., additional

Published
2003
Full Text
View/download PDF

38. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid.

Author

Antiga, E., Quaglino, P., Volpi, W., Pierini, I., Del Bianco, E., Bianchi, B., Novelli, M., Savoia, P., Bernengo, M.G., Fabbri, P., and Caproni, M.

Subjects
T cells, BULLOUS pemphigoid, AUTOIMMUNE diseases, SKIN diseases, IMMUNOHISTOCHEMISTRY, CONFOCAL microscopy, CYTOKINES, FLOW cytometry
Abstract

Background Although regulatory T cells (Tregs) are affected in several autoimmune skin diseases, only two studies have been performed in patients with bullous pemphigoid ( BP) with contrasting results. Objective To characterize Tregs and to determine the serum levels of regulatory cytokines in patients with BP. Methods In BP lesional skin, immunohistochemistry and confocal microscopy were performed for CD4+, CD25+, forkhead/winged helix transcription factor ( FOXP3)+, transforming growth factor ( TGF)-β+ and interleukin ( IL)-10+ cells. In addition, the number of CD4+ CD25++ FOXP3+ Tregs in peripheral blood was assessed by flow cytometry, and the levels of TGF-β and IL-10 were determined in serum samples by enzyme-linked immunosorbent assay before and after steroid therapy. Controls included patients with psoriasis, atopic dermatitis ( AD) and healthy donors. Results The frequency of FOXP3+ cells was significantly reduced in skin lesions from patients with BP ( P < 0.001) compared with psoriasis and AD. Moreover, the number of IL-10+ cells was lower in BP than in psoriasis ( P < 0.001) and AD ( P = 0.002), while no differences were observed in the number of TGF-β+ cells. CD4+ CD25++ FOXP3+ Treg in the peripheral blood of patients with BP was significantly reduced compared with healthy controls ( P < 0.001), and augmented significantly after steroid therapy ( P = 0.001). Finally, TGF-β and IL-10 serum levels were similar in patients with BP compared with healthy controls. However, after therapy, BP patients showed significantly higher IL-10 serum levels than before therapy ( P = 0.01). Conclusions These data suggest that the depletion of Tregs and of IL-10 in patients with BP may be an important factor in the pathogenesis of the disease. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

42. Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study.

Author

Savoia, P., Osella-Abate, S., Deboli, T., Marenco, F., Stroppiana, E., Novelli, M., Fierro, M.T., and Bernengo, M.G.

Subjects
CANCER diagnosis, EPIDEMIOLOGY of cancer, MULTIVARIATE analysis, HISTOPATHOLOGY, HEALTH outcome assessment, MEDICAL statistics, DISEASE progression, FOLLOW-up studies (Medicine)
Abstract

Background Development of more than one primary melanoma in a sole patient is frequent, accounting for 1.2-8.2% of melanoma patients in most recent series. Objective and methods Clinical, histological and epidemiological characteristics of 270 multiple primary melanomas patients were reviewed. Results Two-hundred and seven patients (76.7%) had two melanomas, whereas in the remaining 63 the number of primary ranged from three to eight; on the whole, 639 multiple primary melanomas were identified. Synchronous melanomas developed more frequently in patients with three or more lesions; median age was significantly lower in the group of patients with more than three melanomas than in the others. Mean Breslow's thickness significantly decreases ( P < 0.001) from the first (1.77 ± 1.76 mm) to subsequent primaries (0.85 ± 1.25 mm for the second and 0.66 ± 0.48 mm for the third melanoma). Percentage of ' in situ' melanomas was 5.6% as first diagnosis, but increased to 24.8% for the second melanoma; number of nodular melanomas was significantly lower for succeeding diagnosis. AJCC stage at diagnosis showed a statistical prognostic significance, whereas outcome and survival did not depend on the number of primary lesions. Multivariate analysis confirmed the prognostic role of Breslow's thickness, ulceration, gender and patient age, and the better prognosis of patients with multiple melanomas, respect to those with single primary melanoma. Conclusions Skin examination and long-term follow-up are mandatory for patients affected by melanoma, with the intent to promptly diagnose not only a disease progression but also possible new primary melanomas. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

43. Disease progression in melanoma patients with negative sentinel lymph node: does false-negative specimens entirely account for this phenomenon?

Author

Savoia, P., Fava, P., Caliendo, V., Osella-Abate, S., Ribero, S., Quaglino, P., Macripò, G., and Bernengo, M.G.

Subjects
MELANOMA, DISEASE progression, SENTINEL lymph nodes, DIAGNOSTIC specimens, PROGNOSTIC tests, PATIENTS
Abstract

Background Sentinel lymph node (SLN) status is the most important prognostic factor for subjects with primary melanoma thicker than 1 mm. Objective We focused our study on patients with disease progression after negative SLN biopsy (SLNB), with the aim of elucidating their clinical and histopathological characteristics, outcome and real incidence of false negative. Methods A total of 688 melanoma patients who underwent SLNB (1 May 1998-31 December 2008) were analysed; all patients had Breslow >1 mm or Breslow <1 mm and at least one of the following features: regression, ulceration and/or Clark level IV-V. Results Progression developed in 114 of 503 negative SLN patients (22.7%); the first metastatic site was regional in 64% and distant in 36% of these cases. Thirty-nine patients had nodal metastases in the SLN basin as first site of progression. High-risk melanomas ( P = 0.001) and elderly patients ( P = 0.0005) had an increased probability of progression. Women with a higher median age and lower limbs primary melanoma developed mainly regional skin metastases, while an increased probability of distant metastases was demonstrated in patients with primary on the trunk and axillary SLN ( P = 0.003, P = 0.001 respectively). Age at diagnosis, Breslow thickness and regression showed a prognostic relevance in univariate and multivariate analyses on disease-free survival and overall survival. Conclusions Even if SLN status remains the most important prognostic factor for melanoma patients, progressive disease after a negative SLNB is a relatively frequent event. However, in our opinion, only a part of negative SLNB patients with metastatic spreading should be considered as false negative (7.75%). [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

50. Skin lesions in angioimmunoblastic lymphadenopathy: histological and immunological studies.

Author

Bernengo, M.G., Levi, L., and Zina, G.

Subjects
LYMPHOCYTES, LEUCOCYTES, B cells, T cells, HISTOLOGY, IMMUNOLOGY
Abstract

Angioimmunoblastic lymphadenopathy with dysproteinaemia is reported (AILD) in four patients with different skin pictures. As the disease progresses two main forms predominate: papulonodular and erythroderma. In all cases the histological picture of the skin mirrors that of the lymph-node. Our results point to an increase in the peripheral blood, lymph-nodes and skin of T and subsequently of B lymphocytes suggesting that a proliferation of helper T cells and hence activation of the B-cell subpopulation may be involved in the pathogenesis of some cases of AILD. [ABSTRACT FROM AUTHOR]

Published
1981
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results